Literature DB >> 21136195

Administering intravenous immunoglobulin during infection is associated with infusion reactions in selected patients.

S Khan1, M Abuzakouk, P C Doré, W A C Sewell.   

Abstract

BACKGROUND: Guidelines vary regarding the safety of administering intravenous immunoglobulin (IVIG) during infections, although evidence for this advice is lacking and is based on expert opinion. AIMS: We retrospectively studied patients with common variable immunodeficiency who reacted during IVIG therapy as to whether routinely obtained markers of infection such as C-reactive protein (CRP) were elevated.
METHODS: 19 patients on replacement IVIG therapy in a hospital-based infusion unit were studied. CRP levels obtained were normalized to baseline levels without reactions (defined as 100).
RESULTS: 8 of 19 patients had 16 reactions over a total of 107 infusions. Normalized CRP levels during reactions were higher [mean (±SD) of 258 (±215)] than during infusions with no reaction [mean 100 (±54.9), p = 0.017], and higher than in patients who did not react [mean 100 (±79.7), p = 0.017].
CONCLUSIONS: Some patients with IVIG reactions had elevated CRP levels suggesting that concurrent infection may have caused the reaction. Pre-emptive antibiotic therapy and delaying infusion could prevent unnecessary morbidity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21136195     DOI: 10.1007/s11845-010-0654-4

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  12 in total

1.  Prescribing intravenous immunoglobulin: summary of Department of Health guidelines.

Authors:  Drew Provan; Helen M Chapel; W A Carrock Sewell; Denise O'Shaughnessy
Journal:  BMJ       Date:  2008-10-20

Review 2.  Intravenous immunoglobulin: adverse reactions and management.

Authors:  Francisco A Bonilla
Journal:  J Allergy Clin Immunol       Date:  2008-10-08       Impact factor: 10.793

3.  Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies).

Authors:  M E Conley; L D Notarangelo; A Etzioni
Journal:  Clin Immunol       Date:  1999-12       Impact factor: 3.969

Review 4.  Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.

Authors:  Jordan S Orange; Elham M Hossny; Catherine R Weiler; Mark Ballow; Melvin Berger; Francisco A Bonilla; Rebecca Buckley; Javier Chinen; Yehia El-Gamal; Bruce D Mazer; Robert P Nelson; Dhavalkumar D Patel; Elizabeth Secord; Ricardo U Sorensen; Richard L Wasserman; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2006-04       Impact factor: 10.793

5.  Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin.

Authors:  V M Brennan; N J Salomé-Bentley; H M Chapel
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

6.  Survey of infection in patients receiving antibody replacement treatment for immune deficiency.

Authors:  S J Pettit; H Bourne; G P Spickett
Journal:  J Clin Pathol       Date:  2002-08       Impact factor: 3.411

7.  The course of C-reactive protein response in untreated upper respiratory tract infection.

Authors:  Hasse Melbye; Dag Hvidsten; Arne Holm; Sveine Arne Nordbø; Jan Brox
Journal:  Br J Gen Pract       Date:  2004-09       Impact factor: 5.386

8.  Adverse reactions in selected patients following intravenous infusions of gamma globulin.

Authors:  N K Day; R A Good; V Wahn
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

9.  [Intravenous gamma globulin therapy. Measurement of circulating immune complexes and complement factors].

Authors:  V Wahn
Journal:  Fortschr Med       Date:  1984-08-30

10.  A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation.

Authors:  Benjamin Rhodes; Marilyn E Merriman; Andrew Harrison; Michael J Nissen; Malcolm Smith; Lisa Stamp; Sophia Steer; Tony R Merriman; Timothy J Vyse
Journal:  PLoS Med       Date:  2010-09-21       Impact factor: 11.069

View more
  1 in total

Review 1.  Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective.

Authors:  Manu Shankar-Hari; Jo Spencer; William A Sewell; Kathryn M Rowan; Mervyn Singer
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.